Michigan Urological Surgery Improvement Collaborative

Similar documents
Date Modified: March 31, Clinical Quality Measures for PQRS

Date Modified: May 29, Clinical Quality Measures for PQRS

State-wide Surgical Quality: How We Have Created Change in Michigan

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Active Surveillance (AS) is an expectant management. Health Services Research

Risk Migration ( ct2c=high)

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

Quality of Life After Modern Treatment Options for Prostate Cancer Ronald Chen, MD, MPH

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

Using Markov Models to Estimate the Impact of New Prostate Cancer Biomarkers

R-SCAN: Engaging Clinicians in Value-based Care

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease

PSA Screening and Prostate Cancer. Rishi Modh, MD

AQUA, BAUS, and other registries: a critique

One Stop Prostate Biopsy Protocol Author Consultation Date Approved

Cancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:

FOR PATIENTS DIAGNOSED WITH EARLY-STAGE PROSTATE CANCER. Discover a test that can help you on your treatment journey

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Mr Jeremy Grummet, Urological Surgeon MBBS, MS, FRACS Foundation 49 Men s Health Symposium August 2015

Managing Prostate Cancer in General Practice

The AUA Science & Quality Council. J. Stuart Wolf, Jr., M.D., FACS AUA Science &

Newer Aspects of Prostate Cancer Underwriting

Questionnaire. 1) Do you see men over the age of 40? 1. Yes 2. No

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center

Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer

Screening for Prostate Cancer with the Prostate Specific Antigen (PSA) Test: Recommendations 2014

Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015

PCA MORTALITY VS TREATMENTS

Pre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest

Understanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices

A REPORT ON PRACTICE PATTERN TRENDS IN PROSTATE CANCER

Sommerakademie Munich, June

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News

Prostate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018

BPH with persistently elevated PSA 아주대학교김선일

Prostate Cancer Local or distant recurrence?

Screening and Diagnosis Prostate Cancer

Prostate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality

Providing Treatment Information for Prostate Cancer Patients

Objectives. Prostate Cancer Screening and Surgical Management

Prostate Cancer Incidence

Consensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Radical Prostatectomy:

THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES

Conceptual basis for active surveillance

16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) -

The European Board of Urology

Table of Contents. I. Situation Analysis II. Executive Summary III. Scope of Work: 2017

da Vinci Prostatectomy

Focal Therapy is a Fool s Paradise : The whole prostate must be treated!

10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION

PSA test. PSA testing is not usually recommended for asymptomatic men with < 10 years life expectancy Before having a PSA test men should not have:

Laparoscopic Surgery. The Da Vinci Robot. Limits of Laparoscopy. What Robotics Offers. Robotic Urologic Surgery: A New Era in Patient Care

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH

Prostate disease masterclass. Primary care

Measure #164 (NQF 0129): Coronary Artery Bypass Graft (CABG): Prolonged Intubation National Quality Strategy Domain: Effective Clinical Care

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS

Elsevier Editorial System(tm) for European Urology Manuscript Draft

High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November D. Maruzzi - L. Ruggera

Questions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test

Active Surveillance for Intermediate Risk Prostate Cancer

Otis W. Brawley, MD, MACP, FASCO, FACE

Adam Raben M.D. Helen F Graham Cancer Center

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE

GENE EXPRESSION PROFILING AND PROTEIN BIOMARKERS FOR PROSTATE CANCER MANAGEMENT

State-of-the-art: vision on the future. Urology

NICE BULLETIN Diagnosis & treatment of prostate cancer

DENOMINATOR: Patients aged 18 and older with infrarenal non-ruptured endovascular AAA repairs

PROSTATE CANCER SURVEILLANCE

The Evolving Role of PSA for Prostate Cancer. The Evolving Role of PSA for Prostate Cancer: 10/30/2017

PROSTATE CANCER Amit Gupta MD MPH

Controversies in Prostate Cancer Screening

Michigan Coalition Against Homelessness. Empowering Communities Ending Homelessness

Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer

Area offers new approach to detecting, diagnosing and treating prostate cancer. by ANDREA GABLE

TRT and localized protate cancer

An educational guide from Genomic Health

2017 Merit-based Incentive Payment System. Avoiding the Penalty

THE UROLOGY GROUP

Prostate MRI: Who needs it?

PCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."

Index Lesion Only. Prof. Phillip D Stricker

National Wraparound Initiative Webinar Series. Youth in Wraparound. February 22, Tammy Cherry. Placer County Children's System of Care

Prostate Cancer: 2010 Guidelines Update

Table of Contents

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #10: NCRA /13/17 Eileen Tonner, MS

The Challenge of Cancer Screening Part One Prostate Cancer and Lung Cancer Screening

Financial Disclosures. Prostate Cancer Screening and Surgical Management

Urological Society of Australia and New Zealand PSA Testing Policy 2009

Patterns in the Treatment of Intermediate and High Risk Localized Prostate Cancer

ROBOTIC VS OPEN RADICAL CYSTECTOMY

Attachment #2 Overview of Follow-up

Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation

Prostate Cancer Screening: Con. Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto

National Prostate Cancer Audit. Bill Cross June 2015

Inception Cohort. Center for Evidence-Based Medicine, Oxford VIP-- Inception Cohort (2008) Nov Dec

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer

Transcription:

Michigan Urological Surgery Improvement Collaborative Making Michigan #1 in Prostate Cancer Care Jim Montie, MD Susan Linsell, MHSA February 10, 2015

Vital statistics MUSIC Participants: 42 practices 235 urologists (~90% of urologists in state) 4 patient advocates Data Collection: 36 practices More than 15,000 cases in the registry > 13,500 biopsies and 2,800 radical prostatectomies

Current QI Activities 1. Appropriate imaging 1. Safer prostate biopsy 2. Improve radical prostatectomy perioperative and functional outcomes 3. Appropriate treatment

1. Appropriate Imaging Rationale: Focus of AUA Choosing Wisely Campaign

Imaging 10% Low Risk (PSA <10, GL 6, T1c or T2a) 5% Pre-Intervention Post-Intervention 0% BS CT

Imaging MUSIC data demonstrated a + Bone Scan or CT Scan for intermediate risk patients was rare (<1%) Developed imaging appropriateness criteria based on literature review, guidelines, and MUSIC data with collaborators from UM Industrial Engineering

MUSIC Imaging Appropriateness Criteria Order a Bone Scan if: Order a CT Scan if:» Gleason Score 8 or» PSA >20» Gleason Score 8 or» PSA >20 or» Clinical T Stage T3

MUSIC Imaging Appropriateness Criteria Imaging Goals Perform Imaging in 95% of patients meeting criteria Perform imaging in <10% of patients NOT meeting criteria Do when you should, don t when you shouldn t

Imaging Appropriateness: Collaborative Wide target target target

2. Making Prostate Biopsy Safer Rationale: Increasing sepsis rate nationally to 2-4 % of biopsies

Reducing prostate biopsy-related hospitalizations Baseline prostate biopsy-related hospitalization rate of 1.26% 92% of hospitalizations due to infection 79% of cultures identified a fluoroquinolone resistant organism The challenge is addressing fluoroquinolone resistance

Pathways for addressing Fluoroquinolone resistance

Collaborative-wide hospitalization rates 1.5% 1.16% P = 0.0005 1.0% 0.5% n = 65 n = 65 n = 60 0.60% n = 23 n n = = 25 25 0.0% Pre-Intervention (5,152 biopsies) Post-Intervention (7,823 biopsies)

3. Improving perioperative and functional outcomes after radical prostatectomy Rationale: Morbidity of RP major driver in early detection debate

Post Prostatectomy Perioperative Care At Jan 2014 MUSIC meeting, we presented data that showed our initial method of tracking complications was not reliable or actionable Thus, on March 20, 2014, we changed to tracking how cases followed an uncomplicated pathway of post-op recovery

MUSIC-Notable Outcomes and Trackable Events after Surgery (NOTES) Uncomplicated Recovery Pathway No Rectal Injury EBL < 400mL LOS < 2 days Drain Placement < 2 days Catheter Placement < 16 days No Indwelling Catheter Replacement No 30-day Readmission No 30-day Mortality This pathway allows us to collect objective data that can show a surgeon how perioperative care varies and represents unanticipated events (complication) that can negatively impact patient short-term recovery

Percent Deviated Cases Overall Case Deviation (at least one deviation) Get better Practices

NOTES report

MUSIC Patient Reported Outcomes: so far MUSIC Goals Baseline 3 month 6 month Patients Enrolled 99% 86% 97% 100% Questionnaire Completed 75% 94% 89% 97% Paper Questionnaires <20% 31% 29% 30% Patient Requiring Phone Calls TBD 24% 20% 9% Table Legend: : >10% of MUSIC Goals : <10% of MUSIC Goals : Goal Met

Patient Reported Outcomes: Trend Report

The opportunity in Michigan: 12 case pilot video review assessment Is video assessment by peers or crowd feasible?---yes Are measurable differences evident between surgeons?---yes Does technique/skill correlate with outcomes?---? Can coaching improve performance?---?

4. Appropriate Treatment Rationale: great concern regarding overtreatment

Active Surveillance: favorable practice patterns in Michigan Womble et al, Eur Urol, 2014

Variation and Appropriate Treatment Variation is appropriate when it can be explained by factors that are considered relevant in treatment decisions Variation is inappropriate when explained by insurance status, ethnicity, ancillary profit, etc.

% local therapy Treatment and Life Expectancy Gleason score 3+3=6, PSA 2-6 Any recommendation for Tx Patients receiving any local tx Age

A defined process is used to score specific clinical scenarios as Appropriate, Uncertain, Inappropriate The measures must recognize that patient preferences will trump the criteria in some cases MUSIC development of Appropriate Use Criteria Well-developed RAND/UCLA Method Panel of physicians create a series of detailed clinical scenarios based on a list of parameters

Demonstrating the Value of MUSIC

Participant Engagement Recruitment trips and site visits Regular provider interaction through emails and phone calls Commitment to excellent customer service Working groups (3 6 members) focused on each QI priority Health Policy/Administrative Benefits:» PQRS Qualified Clinical Data Registry» CME

% of Responses Value to clinicians 80% 70% 60% 50% 40% 30% 20% 10% 0% How likely would you be to recommend MUSIC to other urologists who are not members of the collaborative? 71.3% 25.2% 2.6% 0.0% 0.0% 0.9% Very likely Likely Undecided Unlikely Very unlikely Don't Know

Value expressed by a MUSIC patient advocate I just wanted to give you my two cents worth about the subject conference call. My thought is that a video is an excellent way for all to improve. An individual may be doing something a specific way and may not realize that a minor change could have a significant impact on the result. It is a great challenge and a very noble effort to make outcomes for patients better. Thanks for having me part of this interesting process.

Shameless Promotion of MUSIC Perhaps equally important to the data collected are the model and methods themselves. It is remarkable that the MUSIC voluntary effort includes nearly 90 per cent of the urologists in Michigan. This type of clear headed and proactive cooperative thinking and pooling of data which combines best patient guidelines/recommendations with health system financial considerations for medical practice patterns should serve as a model for emulation across the whole span of clinical practice issues. Sagalowsky (UTSW), Editorial in Urology

Value framework *Value = Appropriateness ( Outcomes ) Cost Appropriateness = appropriateness score + patient preference Outcomes = peri-op score + PRO score + cancer control For the first time, I think we can actually tackle value because we can quantify appropriateness, outcomes, and cost *Adapted from D. Spahlinger

Thank you